Invivyd stock faces an October test after LIBERTY results

Published on 10/07/2026 at 05:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Invivyd stock now hinges on LIBERTY data showing 56.5 percent of VYD2311 recipients versus 91.4 percent with an mRNA vaccine. Q2 revenue rose 21 percent to USD 14.3 million.

IVVD, US00534A1025, Illustration mit AI erstellt.

Invivyd, Inc. (ISIN US00534A1025) was last at USD 0.81 on Nasdaq on October 6, 2026, down 3.91 percent from the previous close. The company has put its next major value driver in October, when DECLARATION safety and immunogenicity data for VYD2311 are expected.

LIBERTY delivers a clear comparison

According to Invivyd in its September 29, 2026 release, the Phase 3 LIBERTY study enrolled 210 healthy adults and tested a 250 mg VYD2311 dose. Over six days, 56.5 percent of participants receiving VYD2311 experienced a treatment-emergent adverse event, injection-site reaction or hypersensitivity, compared with 91.4 percent in the mRNA vaccine arm.

The comparison extended beyond the headline safety measure. Systemic adverse events occurred in 44.1 percent of VYD2311 recipients versus 68.1 percent with the vaccine, while the 56-day overall event rate was 60.9 percent versus 91.4 percent. The company said it intends to pursue a Biologics License Application through the FDA Accelerated Approval Program if the DECLARATION results support that route.

Revenue grows as losses widen

Invivyd's commercial business provides a second, smaller part of the story. StockTitan reported that Q2 2026 PEMGARDA net product revenue reached USD 14.3 million, up 21 percent from USD 11.8 million in Q2 2025. Cash and cash equivalents stood at USD 160.1 million on June 30, 2026.

The cost of advancing VYD2311 remains visible in the income statement. Invivyd's Q2 2026 net loss widened to USD 44.4 million from USD 14.7 million in the prior-year quarter, while research and development expense rose to USD 29.4 million from USD 9.6 million. For investors, the October readout must therefore address both clinical differentiation and the funding needed to reach a potential launch.

IVVD remains below its yearly high

IVVD's October 6, 2026 price of USD 0.81 was inside its 52-week range of USD 0.53 to USD 3.07 and came with volume of 5,043,390 shares. The company had a market capitalization of USD 237.6 million as of October 6, 2026.

Consensus data from Paasa show a Buy rating based on 8 analysts, with targets ranging from USD 9.00 to USD 10.00 and a median target of USD 9.50. The median target lies 1,074.1 percent above the October 6 price, making the upcoming clinical data the central test behind that unusually wide valuation gap.

October data sets the next checkpoint

DECLARATION is a Phase 3 placebo-controlled study designed to evaluate VYD2311 for prevention of symptomatic COVID-19. The September 29 release links the planned regulatory submission to safety and immunogenicity data first, while clinical efficacy events are intended to remain part of a later confirmatory process.